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Dr Mark D. Rodefeld (Indianapolis, Ind). I would like to
congratulate Dr Hoganson on a very good presentation, and I
would also like to thank you for providing me the report in
advance.
I congratulate the Washington University group for their work
in a very challenging subset of patients and for leading the way
in new therapies to treat them. In this report, Dr Hoganson has
summarized their experience with the use of paracorporeal lung
assist devices to support neonates and young children with primary
respiratory failure who are awaiting LT. Clearly, thewaiting period
for a suitable lung donor can be long, and many patients will not
survive this waiting period.
This study, which was essentially a feasibility study, with a total
of 4 patients, has shown that it is possible to successfully bridge
these patients to LT using a paracorporeal oxygenator alone.
Patients can be extubated, and this has obvious implications with
regard to quality of life.
The alternative support modality is ECMO, which has a limited
span of its own and also complicated issues of its own. In patients
with primary lung failure, ventricular or pump failure might not be
a problem, and, therefore, an oxygenator alone might be a feasible
therapy. There is no question that this is a challenging group of
patients.
I have several questions.
You might have mentioned it; I did not see it in the report, but
how many oxygenator changes were required in these patients?
Dr Hoganson. One of the patients required 2 oxygenator
changes. We did that at the bedside just by providing some
additional support and clamping the circuit, it can be done in
60 seconds. One additional oxygenator change occurred in
another patient, so 3 total. That was 1 of the real advantages
with the Quadrox—being able to monitor the pre- and postoxyge-
nator pressures. You can see sort of at the bottom of this chart that
that is actually the transoxygenator gradient, and we were able to
see whether that had increased. It is certainly a marker of potential
thrombus buildup and that was an indication to change the
oxygenator, so it was nice to have that marker for these patients.426 The Journal of Thoracic and Cardiovascular SurgDr Rodefeld. Were the devices examined for clot burden after
they were removed?
Dr Hoganson. You know, they were, and we did not see any.
Also, even at the end of this particular patient’s course when LA
thrombus was involved in that pump exchange, we fully flushed
out the thrombus. A few were present in the oxygenator, a few
specks of thrombus, but not a significant burden by any stretch,
despite withholding anticoagulation for the previous several days.
Dr Rodefeld. A significant number of strokes occurred in this
series of 4 patients. Were any of the strokes temporally related
to the oxygenator change?
Dr Hoganson. The stroke in the 23-month-old patient was
related to a bedside event when he was extubated and actually
kicked the cannula off the oxygenator and experienced a hemor-
rhagic event at the bedside. Thankfully that was immediately
stopped. He was taken to the operating room, and the device was
weaned that day. He had an embolic stroke found on imaging after
that. It is certainly a question whether hypotension precipitated the
clinical events of that stroke. That was an unusual occurrence.
The other 2 strokes we have certainly presumed were somehow
related to LA thrombus that built up as a result of the metal tip
projection into the LA.
Dr Rodefeld. So, you are more concerned about cannulation
issues as being the source of stroke?
DrHoganson.Yes, I think that was our greatest concern about a
potential etiology for the other 2 strokes.
Dr Rodefeld. It seemed as though all the patients required
ECMO support, but they had had highly variable amounts of
time from ECMO support to support by an oxygenator alone.
What were the factors influencing the decision there?
Dr Hoganson. It was mostly related to our maturation of an
understanding of when we might use this support. The first patient
received ECMO for 17 days. Obviously, once it was conceived, it
required time to get supplies in and the approval and such. The 1
patient was treated for 10 days; that was actually the second
patient. We had conceived the idea before that patient began
ECMO that perhaps we would need to use this because the
presumed diagnosis was ACD because of an older sibling who
had had it. Then, for the patient with AV canal right lung
hypoplasia, we had often discussed potentially putting this patient,
who was struggling, on this device. However, because it is a new
device, we wanted to proceed only after the patient had met the
indications for ECMO. We did not put many patients de novo on
the support. This patient was emergently given ECMO at the
bedside, and we just decided to take it down that day. It was really
an evolution as we decided who might or might not be candidates.
Dr Rodefeld. Next question. Can you foresee the possibility of
transitioning a patient directly to an oxygenator alone and not
using the intervening ECMO?
Dr Hoganson. Yes, I think so. Since this series, we have
discussed it for a couple patients. We have been struggling to
potentially avoid that other procedure and the potential for
complications. I think once we are more comfortable with which
patients will be good candidates and whowould be well supported,
we will be willing to do that.
Dr Rodefeld. ECMO obviously has its own complications and
problems that come with it, a morbidity that comes with it.
Perhaps, if a better device were available, direct conversion toery c January 2014
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Doxygenator therapy might be easier to envision, because you could
potentially avoid some of the issues that come with ECMO alone.
Also, that transitions me to my last question, which is, I know
you have done some basic work in this area. What would you
foresee as the ideal oxygenator or paracorporeal lung device? In
the best of all possible worlds, we would prefer to have a device
that we could use that has been designed expressly for passive
flow conditions. You have reported on use of a device that was
designed for use in an ECMO circuit and not expressly designed
for passive flow use.
Dr Hoganson. Right. Sometimes one is at the right place at the
right time. Also, I have done a lot of work in this area, as you
alluded, so for the past 7 years, we have been working on an
engineered lung assist device for this purpose. Also, the approach
we have been taking is an engineering approach to create
hemodynamically perfect blood flow in an engineered vasculature.
I think this, combined with using a biomaterial within the scaffold,
we will be able to have both perfect blood flow and endothelializa-
tion and thus no longer require using high-dose anticoagulation
and could use either low or no anticoagulation. I think that will
afford us a number of potential clinical options.
Certainly, the patients we have talked about today with a
paracorporeal lung assist device would be perfect candidates, in
addition to treating premature infants with premature lung disease
and umbilical cannulation directly at birth without intubating
them, potentially allowing some lung growth. Also, for older
adolescents or adults, I think potential will exist, just as others
have described, for an implantable lung assist device that could
be a bridge to LT or possibly a destination therapy after a left
ventricular assist device-type of maturation. I think really focusing
on physiologic blood flow and endothelialization in a lung device
will provide good support for these patients.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). I enjoyed your
presentation. Obviously you have been treating a very challenging
group of patients. In Toronto, we have treated about 15 of these
patients with a PA-to-LA Novalung configuration. Granted most
of them were adults, but we have used this in children, down to
about 20 kg in weight. We have used a simple PA cannula and
LA cannula, either in the superior pulmonary vein or the LA
appendage, and we really have not had any stroke problems at
all. We moved to extubation, waking up, and ambulating, just as
you presented in the picture of 1 of our patients.
I wondered why you chose to use the trans-right atrial
cannulation technique with the interposition graft, the Berlin heart
cannula? That appears to complicate the situation. In the setting of
a low-flow situation, this might be a setup for stroke complications.
Dr Hoganson. Yes, I think a number of factors could have
contributed to why our reasonably small infants had issues that
your older patients did not. Certainly, 1 of the questions we were
unable to answer with these patients was how much blood flow
goes through the oxygenator and how much goes through the
native lungs. Also, echocardiography of the neonate showed
reversal of pulmonary blood flow in the pulmonary vascular and
a huge jet coming out of the cannula and a very small amountThe Journal of Thoracic and Cacoming out of the pulmonary vein. I think the overall majority
of the blood flow was coming through the oxygenator, and I think
that just set up a flow pattern sort of behind the metal tip right angle
cannula that led to some stasis, and I think that is the hemodynamic
explanation. Also, I think it was a very small atrium.
Dr del Nido. If you put a flow probe on your circuits, you
will measure what is going out across the circuit and, with a
low-resistance membrane, you can adjust that and know exactly
what is occurring.
Dr Hoganson. But the contribution of the native lungs we
were unable to state. Thus, I think that is a hemodynamic expla-
nation. Also, I think, certainly for 1 patient, they had intermittent
holding of the anticoagulation for the 10 days before death, and
perhaps that contributed to the LA thrombus in that patient. I
think that was likely. The other patient had full anticoagulation
for several weeks before the autopsy and so I do not think that
was the case. Thus, I agree. I think we certainly thought it was
going to be fine, on the basis of your work. Also, because we
had some serious clinical issues, we decided to use a different
approach.
DrKeshavjee. The point is that what is going through the native
pulmonary circulation in this patient at this point is essentially
irrelevant. If the patients are hemodynamically stable and have
flow going through the Novalung, that is what is keeping them
alive and decompressing the right side. As the pulmonary
circulation becomes better, such as in your patient who did get
better and could be weaned off, the flow in the Novalung will
decrease, so it balances itself.
Dr del Nido. Dr Keshavjee, and David for you, there is some
experience in France in treating primary pulmonary hypertension,
not in patients who are hypoxic, by creating a shunt between the
PA and the descending aorta, with some very encouraging results.
Can you comment on the potential role of this procedure.
Obviously, if you have primary lung failure or lung problems,
that is not an issue. However, for primary pulmonary hypertension,
could you comment on the role of both these techniques.
Dr Keshavjee. The issue with primary pulmonary hypertension
and the particular option we have been discussing, where you can
go PA to LA, is that you correct the physiology with your device.
You offload the right heart and provide a low vascular resistance
route to pump across.
The problem with the aorta-to-PA shunt is that it does not fix the
physiology for the lung. In those 4 or 5 cases in France, they did
have good palliation. We tried it once in a child, and it did not
work well. Within about 36 hours, we had to go back, undo the
shunt, and put a Novalung in. We got that patient through, but it
was pretty close. Thus, the PA to aorta shunt did not fix that
particular challenging patient for us. However, we did discuss it
extensively, the appeal being that if you are really worried about
whether you can successfully bridge the child to LT, it might be
better to not require a device. We have pushed, however,
toward saying we will get a lung, and we have bridged children
for 6 months on the device—that is enough time to get a lung
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